| LUMASIRAN SODIUM | None | ||
| 94.5MG/0.5ML |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| OXLUMO is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. | |||
|
Yes
| |||
| OXLUMO | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||
| ************ ********** ** ******** ****** *** **************** | ************ ********** ** ******** ****** *** **************** | ******* *** ************ *** *** ******** ********** ** ********* ******* (****) ** ******-******** *** | *************** ** *** ************ ****** | ******* *** ************ *** *** ******** ********** ** ********* ******* (****) ** ******-******** *** | ******* *** ************ *** *** ******** ********** ** ********* ******* (****) ** ******-******** *** | ************ *** ******* *** ********** ** **** (*********** ******* * (********* *******)) **** ********** | ******* *** ************ *** *** ******** ********** ** ********* ******* (****) ** ******-******** *** | ******** ******-******** *** ****** | ******** ******-******** *** ****** | ******* *** ************ *** *** ******** ********** ** ********* ******* (****) ** ******-******** *** | ******* *** ********** ** **** (*********** ******* * (********* *******)) **** ********** | ******** ******-******** *** ****** | ************ *** ******* *** ********** ** **** (*********** ******* * (********* *******)) **** ********** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|